IL2 and melanoma: Another study found that EZH2 inactivation reversed the resistance to anti-CTLA-4 and IL-2 immunotherapy and suppressed melanoma growth in a consequence of accumulating IFN γ, producing PD-1 low CD8+ T cells and PD-L1 downregulation on melanoma cells [205].